| Palbociclib studied in …STUDIED_INderived200 of 284show all (up to 200) |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 284 trials list this drug (108 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04072952Phase 1/Phase 2 · completed A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 284 trials list this drug (108 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04711252Phase 3 · active not recruiting A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05867251Phase 1/Phase 2 · recruiting Study of AVZO-021 in Patients With Advanced Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07492641Phase 3 · recruiting BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01723774Phase 2 · active not recruiting PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06377852Phase 3 · recruiting The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03573648Phase 2 · active not recruiting Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04224272Phase 2 · completed Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05384119Phase 1 · terminated Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04964934Phase 3 · active not recruiting Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06126276Phase 2 · recruiting Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) · 284 trials list this drug (108 active) | — | — | Malignant Solid Neoplasm,Malignant Female Reproductive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04966481Phase 3 · recruiting Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07174336Phase 3 · recruiting A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03455270Phase 1 · completed G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Breast Ductal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04693468Phase 1 · recruiting Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial · 284 trials list this drug (108 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05694871Phase 2 · active not recruiting Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma · 284 trials list this drug (108 active) | — | — | Dedifferentiated Liposarcoma,Soft Tissue Sarcoma of the Trunk and Extremities | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06843967Phase 1/Phase 2 · recruiting A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma · 284 trials list this drug (108 active) | — | — | Liposarcoma,Round Cell Liposarcoma,Dedifferentiated Liposarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748208Phase 2 · not yet recruiting A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04438824Phase 2 · active not recruiting Palbociclib and INCMGA00012 in People With Advanced Liposarcoma · 284 trials list this drug (108 active) | — | — | Liposarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06065748Phase 3 · active not recruiting A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03147287Phase 2 · active not recruiting Palbociclib After CDK and Endocrine Therapy (PACE) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191499Phase 2/Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03424005Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04931342Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 284 trials list this drug (108 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05226871Phase 2 · active not recruiting Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm,Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03006172Phase 1 · active not recruiting To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer · 284 trials list this drug (108 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07347600recruiting A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03820830Phase 3 · active not recruiting Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802759Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06380751Phase 3 · recruiting Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04288089Phase 1 · active not recruiting A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02536742Phase 2 · completed Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03644186Phase 2 · completed To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) · 284 trials list this drug (108 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07787520Phase 1 · not yet recruiting A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04360941Phase 1 · active not recruiting PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554367Phase 2 · active not recruiting Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial · 284 trials list this drug (108 active) | — | — | Malignant Solid Neoplasm,Malignant Pancreatic Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05468697Phase 1/Phase 2 · active not recruiting A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) · 284 trials list this drug (108 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06962969completed A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07123090Phase 2 · recruiting A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · 284 trials list this drug (108 active) | — | — | Malignant Kidney Neoplasm,Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03454035Phase 1 · recruiting Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm,Melanoma,Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959891Phase 1 · active not recruiting AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05069038Phase 2 · active not recruiting Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04546009Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04862663Phase 3 · active not recruiting Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03332797Phase 1 · active not recruiting A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06188520Phase 1/Phase 2 · recruiting A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors · 284 trials list this drug (108 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03304080Phase 1/Phase 2 · active not recruiting Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02942355Phase 2 · active not recruiting Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm,Female Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155620Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · 284 trials list this drug (108 active) | — | — | Hepatoblastoma,Malignant Germ Cell Tumor,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03478514Phase 2 · active not recruiting Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma · 284 trials list this drug (108 active) | — | — | B-Cell Malignant Neoplasm,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07683754Phase 3 · not yet recruiting T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03065387Phase 1 · terminated Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation · 284 trials list this drug (108 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02896335Phase 2 · recruiting Palbociclib and Pembrolizumab In Central Nervous System Metastases · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238922Phase 1 · active not recruiting Study of INCB123667 in Subjects With Advanced Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06390839Phase 2 · active not recruiting Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) · 284 trials list this drug (108 active) | — | — | Lymphoma,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06003114completed A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06997029Phase 1 · recruiting A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439201Phase 2 · active not recruiting Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) · 284 trials list this drug (108 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04567420Phase 2 · active not recruiting DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02605486Phase 1/Phase 2 · active not recruiting Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05768139Phase 1/Phase 2 · recruiting First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors · 284 trials list this drug (108 active) | — | — | Adult Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02764541Phase 2 · active not recruiting Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02513394Phase 3 · active not recruiting PALbociclib CoLlaborative Adjuvant Study · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05563220Phase 1/Phase 2 · active not recruiting Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02738866Phase 2 · active not recruiting Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06570031Phase 1 · completed ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02159755Phase 1 · active not recruiting Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma · 284 trials list this drug (108 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06113809Phase 1 · recruiting Palbociclib and Pembrolizumab in Sarcoma · 284 trials list this drug (108 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03870919NA · active not recruiting Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06760637Phase 3 · active not recruiting Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02297438Phase 3 · completed A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03609047Phase 2 · active not recruiting Adjuvant Palbociclib in Elderly Patients With Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03633331Phase 2 · completed Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03784014Phase 3 · completed Molecular Profiling of Advanced Soft-tissue Sarcomas · 284 trials list this drug (108 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02664935Phase 2 · completed National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer · 284 trials list this drug (108 active) | — | — | Adenocarcinoma,Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05683418Phase 1 · recruiting A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03389477Phase 2 · active not recruiting Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma · 284 trials list this drug (108 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04996160Phase 1 · completed Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia · 284 trials list this drug (108 active) | — | — | Acute Lymphoblastic Leukemia,Childhood Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04606446Phase 2 · recruiting Study of PF-07248144 in Advanced or Metastatic Solid Tumors · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03132454Phase 1 · active not recruiting Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia · 284 trials list this drug (108 active) | — | — | Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04920708Phase 2 · active not recruiting Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression · 284 trials list this drug (108 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02630693Phase 2 · completed Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04841148Phase 2 · recruiting Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05399329completed Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03526250Phase 2 · completed Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) · 284 trials list this drug (108 active) | — | — | Hepatoblastoma,Malignant Germ Cell Tumor,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06654297Phase 1 · active not recruiting Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas · 284 trials list this drug (108 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04654208recruiting Swedish Ibrance Registries Insights (SIRI) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03297606Phase 2 · recruiting Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) · 284 trials list this drug (108 active) | — | — | Solid Neoplasm,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05039177Phase 1/Phase 2 · completed A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies · 284 trials list this drug (108 active) | — | — | Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06736704Phase 1/Phase 2 · recruiting SNV4818 in Participants With Advanced Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627232Phase 1 · recruiting Tazemetostat and Palbociclib With CPX-351for R/R AML · 284 trials list this drug (108 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03446157Phase 2 · completed Palbociclib and Cetuximab in Metastatic Colorectal Cancer · 284 trials list this drug (108 active) | — | — | Colon Neoplasm,Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02905318Phase 2 · active not recruiting Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer · 284 trials list this drug (108 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02778685Phase 2 · active not recruiting Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer · 284 trials list this drug (108 active) | — | — | Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03065062Phase 1 · suspended Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm,Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02947685Phase 3 · active not recruiting Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03170206Phase 1 · completed Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer · 284 trials list this drug (108 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02499146Phase 1 · completed Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05501886Phase 3 · active not recruiting Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02668666Phase 2 · completed Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03685331Phase 1 · completed HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07002177Phase 1/Phase 2 · recruiting A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC · 284 trials list this drug (108 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02760030Phase 2 · completed Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04563507Phase 2 · recruiting Combined Immunotherapies in Metastatic ER+ Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04671615completed A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel. · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06753747Phase 1/Phase 2 · recruiting A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma · 284 trials list this drug (108 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06495164active not recruiting A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03284957Phase 1/Phase 2 · terminated Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05266105Phase 1 · active not recruiting A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03079011Phase 3 · completed PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06086340completed Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05935748Phase 2 · terminated Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) · 284 trials list this drug (108 active) | — | — | Neoplasm,Neoplasm by Site,Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04185883Phase 1 · active not recruiting Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) · 284 trials list this drug (108 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03535506Phase 2 · terminated Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery · 284 trials list this drug (108 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07191977Phase 2 · not yet recruiting Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05216432Phase 1 · recruiting First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | Breast Neoplasm,Solid Neoplasm,Adult Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04478266Phase 3 · terminated Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01907607Phase 2 · completed Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib · 284 trials list this drug (108 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01356628Phase 2 · completed A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer · 284 trials list this drug (108 active) | — | — | Liver Neoplasm,Hepatocellular Carcinoma,Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06947811Phase 1/Phase 2 · recruiting A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05759949Phase 1 · completed First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm,Adult Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03472573Phase 1 · completed Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia · 284 trials list this drug (108 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02040857Phase 2 · completed Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05432518early Phase 1 · recruiting Pilot Trial for Treatment of Recurrent Glioblastoma · 284 trials list this drug (108 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06940349Phase 1/Phase 2 · recruiting Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06941142Phase 1 · not yet recruiting A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498378Phase 1 · active not recruiting Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · 284 trials list this drug (108 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06895733Phase 1/Phase 2 · recruiting Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) · 284 trials list this drug (108 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03792256Phase 1 · completed Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) · 284 trials list this drug (108 active) | — | — | Acute Leukemia,Lymphoblastic Lymphoma,Lymphoid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06856200NA · recruiting A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03691493Phase 2 · completed Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis · 284 trials list this drug (108 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03774472Phase 1/Phase 2 · completed Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04423185Phase 2 · recruiting PLATFORM Study of Precision Medicine for Rare Tumors · 284 trials list this drug (108 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05178888Phase 1 · completed Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) · 284 trials list this drug (108 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03854903Phase 1 · completed WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06805812recruiting Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study · 284 trials list this drug (108 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03709680Phase 2 · active not recruiting Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm,Rhabdoid Tumor,Ewing Sarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04256941Phase 2 · terminated Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study · 284 trials list this drug (108 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06525675completed Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02491983Phase 2 · completed Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05293964Phase 1 · active not recruiting Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02530320Phase 2 · completed Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved · 284 trials list this drug (108 active) | — | — | Oligoastrocytoma,Oligodendroglioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692491Phase 2 · not yet recruiting Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · 284 trials list this drug (108 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01740427Phase 3 · completed A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03238196Phase 1 · completed Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04060862Phase 1 · terminated A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03900884Phase 1 · active not recruiting Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02028507Phase 3 · completed Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02913430early Phase 1 · completed Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06607601completed CARE Initiative: Real-world Emulation of the PALOMA-2 Trial · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03981614Phase 2 · completed Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer · 284 trials list this drug (108 active) | — | — | Carcinoma,Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04946864Phase 1/Phase 2 · suspended A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer · 284 trials list this drug (108 active) | — | — | Adult Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03530696Phase 2 · completed T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer · 284 trials list this drug (108 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03560531Phase 1/Phase 2 · completed A Study of ZN-c5 in Subjects With Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04129151Phase 2 · terminated Palbociclib + Ganitumab In Ewing Sarcoma · 284 trials list this drug (108 active) | — | — | Sarcoma,Ewing Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06478927NA · recruiting Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib · 284 trials list this drug (108 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02599714Phase 1 · completed Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02448420Phase 2 · completed Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01942135Phase 3 · completed Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06338644unknown Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03423199Phase 3 · unknown PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03007979Phase 2 · completed Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02022982Phase 1 · completed PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03024489Phase 1/Phase 2 · unknown Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma · 284 trials list this drug (108 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06307249Phase 1 · recruiting Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA · 284 trials list this drug (108 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Malignant Breast Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03322215Phase 2 · terminated HR+/HER2- Advanced Breast Cancer and Endocrine Resistance · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03709082Phase 1/Phase 2 · terminated Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 284 trials list this drug (108 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03936270Phase 2 · completed Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer · 284 trials list this drug (108 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 284 trials list this drug (108 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03242382Phase 2 · unknown Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. · 284 trials list this drug (108 active) | — | — | Chordoma,Osteosarcoma,Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238831early Phase 1 · withdrawn SMMART Adaptive Clinical Treatment (ACT) Trial · 284 trials list this drug (108 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03471663Phase 1 · completed A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04720768Phase 1/Phase 2 · unknown Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE · 284 trials list this drug (108 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04870034early Phase 1 · withdrawn Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer · 284 trials list this drug (108 active) | — | — | Malignant Solid Neoplasm,Pancreatic Carcinoma,Colorectal Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101034Phase 1/Phase 2 · completed PD 0332991 and Cetuximab in Patients With Incurable SCCHN · 284 trials list this drug (108 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03386929Phase 1/Phase 2 · terminated Survival Prolongation by Rationale Innovative Genomics · 284 trials list this drug (108 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05949424Phase 4 · unknown OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults · 284 trials list this drug (108 active) | — | — | Breast Carcinoma,Ovarian Carcinoma,Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03088059Phase 2 · unknown Biomarker-based Study in R/M SCCHN · 284 trials list this drug (108 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06076772not yet recruiting Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02897375Phase 1 · completed Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors · 284 trials list this drug (108 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Head and Neck Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06065592Phase 1 · unknown Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms · 284 trials list this drug (108 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Malignant Breast Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03158389Phase 1/Phase 2 · completed NCT Neuro Master Match - N²M² (NOA-20) · 284 trials list this drug (108 active) | — | — | Adult Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02499120Phase 2 · completed Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer · 284 trials list this drug (108 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03809988Phase 2 · completed PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05176288Phase 2 · withdrawn Avelumab, Palbociclib and Axitinib in Advanced RCC · 284 trials list this drug (108 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02154490completed Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer · 284 trials list this drug (108 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05865132Phase 2 · unknown Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction · 284 trials list this drug (108 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05135104unknown Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04801966NA · terminated Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study · 284 trials list this drug (108 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04872608Phase 1 · withdrawn A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03065621Phase 2 · completed Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA) · 284 trials list this drug (108 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03285568completed Patterns of Prescribing and Monitoring of Palbociclib · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03110744Phase 2 · completed CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma · 284 trials list this drug (108 active) | — | — | Chordoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03921866completed UK Ibrance Patient Program (IPP) Study · 284 trials list this drug (108 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05766410Phase 2 · recruiting A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC · 284 trials list this drug (108 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02894398Phase 2 · completed Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant · 284 trials list this drug (108 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |